Triple-Drug cocktail takes aim at rare, aggressive cancers
NCT ID NCT07510594
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase 2 trial tests a combination of three drugs—benmelstobart (an immunotherapy), anlotinib (a targeted therapy), and standard chemotherapy—as a first treatment for people with large-cell neuroendocrine carcinoma of the lung or similar cancers outside the lung. The study aims to see how many patients' tumors shrink significantly. It will enroll 48 adults who have not had prior treatment for advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE-CELL NEUROENDOCRINE CARCINOMA OF THE LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy), and chemotherapy (carboplatin or cisplatin plus etoposide)
What this could lead to
If successful, this combination could become a new first-line treatment option for patients with these rare and aggressive cancers, potentially improving tumor shrinkage rates.
What could go wrong
This is a small, early-phase (Phase 2) single-center study with only 48 participants. The combination may cause significant side effects, and results may not apply to broader populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.